A patient treated for acute immune TTP has melena while receiving caplacizumab. Which molecular interaction is inhibited by this drug and explains bot...

Question

A patient treated for acute immune TTP has melena while receiving caplacizumab. Which molecular interaction is inhibited by this drug and explains both efficacy and bleeding risk?

Accepted Answer

Platelet glycoprotein-Ib binding to the VWF A1 domain

Answer

ADAMTS13 binding to the VWF A2 domain

Answer

Complement C5 binding to terminal convertase complexes

Answer

Platelet alpha-IIb-beta-3 binding to circulating fibrinogen

Answer

P-selectin binding to its leukocyte glycoprotein ligand

Transfusion Thresholds-Cardiovascular Disease — MRCP Part 1 MCQ

A patient treated for acute immune TTP has melena while receiving caplacizumab. Which molecular interaction is inhibited by this drug and explains both efficacy and bleeding risk?